| Naveed Ahmed, MD | |
|
911 Bypass Rd Bldg A, Pikeville, KY 41501-1689 | |
| (606) 430-2208 | |
| (606) 218-7508 |
| Full Name | Naveed Ahmed |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 42 Years |
| Location | 911 Bypass Rd Bldg A, Pikeville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508946070 | NPI | - | NPPES |
| 64345838 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 34583 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pikeville Medical Center | Pikeville, KY | Hospital |
| University Of Kentucky Hospital | Lexington, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pikeville Medical Center Inc | 6709790157 | 314 |
News Archive
Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.
The U.S. Food and Drug Administration has approved a humanitarian device exemption for the first implantable device that delivers intermittent electrical therapy deep within the brain to suppress the symptoms associated with severe obsessive-compulsive disorder (OCD).
Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.
NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.
› Verified 3 days ago
| Entity Name | Pikeville Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528195864 PECOS PAC ID: 6709790157 Enrollment ID: O20040304001281 |
News Archive
Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.
The U.S. Food and Drug Administration has approved a humanitarian device exemption for the first implantable device that delivers intermittent electrical therapy deep within the brain to suppress the symptoms associated with severe obsessive-compulsive disorder (OCD).
Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.
NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Naveed Ahmed, MD Po Box 432, Pikeville, KY 41502-0432 Ph: (606) 430-2208 | Naveed Ahmed, MD 911 Bypass Rd Bldg A, Pikeville, KY 41501-1689 Ph: (606) 430-2208 |
News Archive
Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.
The U.S. Food and Drug Administration has approved a humanitarian device exemption for the first implantable device that delivers intermittent electrical therapy deep within the brain to suppress the symptoms associated with severe obsessive-compulsive disorder (OCD).
Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.
NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.
› Verified 3 days ago
Dr. Sujata Rao Gutti, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 515 N Bypass Rd, Suite 101, Pikeville, KY 41501 Phone: 606-437-4100 Fax: 606-432-6009 | |
Christa Muckenhausen, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 100 Lr Johnson Dr, Pikeville, KY 41501 Phone: 606-432-6004 Fax: 606-432-6644 | |
Jay Vallabh Narola, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1330 South Mayo Trail, Nova Complex Ste 101, Pikeville, KY 41501 Phone: 606-432-7233 Fax: 606-432-7255 |